Journal of clinical virology plus最新文献

{"title":"Genomic analysis of SARS-CoV-2 sequences obtained in Tanzania during the pandemic","authors":"Nicholaus P. Mnyambwa ,&nbsp;Jinxin Gao ,&nbsp;Alex Magesa ,&nbsp;Edina Mgimba ,&nbsp;Swaminathan Mahesh ,&nbsp;Pawan Angra ,&nbsp;Juma Kisuse ,&nbsp;Clara Lubinza ,&nbsp;Lawrence Mapunda ,&nbsp;Aman Wilfred ,&nbsp;Godfather Kimaro ,&nbsp;George P. Judicate ,&nbsp;Ambele Eliah ,&nbsp;Augustino Msanga ,&nbsp;Senkoro Mbazi ,&nbsp;Esther Ngadaya ,&nbsp;Mukurasi Kokuhabwa ,&nbsp;Jackson P. Mushumbusi ,&nbsp;Medard Beyanga ,&nbsp;Wangeci Gatei ,&nbsp;Sayoki Mfinanga","doi":"10.1016/j.jcvp.2025.100212","DOIUrl":"10.1016/j.jcvp.2025.100212","url":null,"abstract":"<div><h3>Background</h3><div>Genomic sequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from Tanzania remain scarce in GISAID, thus hindering our understanding of how the pandemic evolved in the country.</div></div><div><h3>Methods</h3><div>We performed whole genome sequencing on SARS-CoV-2 samples collected between March 2021 and December 2022 to characterize the virus in Tanzania. Nasal and oropharyngeal swabs were collected from patients seeking health care, incoming travelers as well as from outgoing travelers undergoing pre-travel COVID-19 testing (required for flight boarding). Sample collection, and testing were coordinated by the National Public Health Laboratory.</div></div><div><h3>Results</h3><div>Among 515 samples, 260 (50.49 %) were from outgoing travelers, 227 (44.08 %) Covid-19 suspects seeking care, and 28 (5.44 %) incoming travelers identified at the airport. The majority of the samples came from Dar es Salaam (<em>n</em> = 380, 73.7 %), the country's largest city and the main port of entry. We identified 74 Pango lineages from all the samples, with Omicron 430 (83.50 %) and Delta 79 (15 %) variants being predominant. From the 380 Dar es Salaam samples, 67 Pango lineages were identified, showing both overlapping and unique lineages in each sample type.</div></div><div><h3>Conclusion</h3><div>Our findings reveal a dynamic circulation of SARS-CoV-2 variants over time, with Delta predominantly observed in 2021 and Omicron in 2022 in Tanzania. The temporal prevalence of the identified lineages was consistent with the global epidemiology of the virus. Sustained and expanded genomic surveillance is recommended to track and respond effectively to emerging variants.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100212"},"PeriodicalIF":1.6,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B and C infection in tuberculosis patients in the Hauts Bassins region of Burkina Faso, West Africa","authors":"Armel Moumouni Sanou ,&nbsp;Abdoulaye Dera ,&nbsp;Jeoffray Diendere ,&nbsp;Nina Mathuola Geneviève Ouattara ,&nbsp;Eric Kyelem ,&nbsp;Arhouna Siguina Traore ,&nbsp;Arouna Dao ,&nbsp;Arielle Sandra Bettina Badiel ,&nbsp;Ina Marie Angèle Traore ,&nbsp;Michel Kiréopori.B Gomgnimbou ,&nbsp;Isidore Bonkoungou ,&nbsp;Gautier Henri Ouedraogo","doi":"10.1016/j.jcvp.2025.100211","DOIUrl":"10.1016/j.jcvp.2025.100211","url":null,"abstract":"<div><div>Tuberculosis (TB) and viral hepatitis B and C represent significant public health concerns. Co-infection with TB and hepatitis B and/or C results in significant complications, including suboptimal treatment outcomes in TB and the development of hepatitis induced by anti-TB drugs. At present, no data on these co-infections are available for Burkina Faso. This study investigates the epidemiology of these co-infections in TB patients in the Hauts-Bassins region of Burkina Faso. A cross-sectional analytical study was conducted in health facilities involved in the management of TB in the Hauts-Bassins region of Burkina Faso from October 2023 to June 2024. For each consenting TB patient, data were collected. A blood sample was obtained and analyzed for a range of infection markers (HBsAg, HBV DNA, anti-HCV antibodies, and HCV RNA) and liver enzymes (ALT and γ-GT). A total of 259 TB patients were included in the study. The mean age of the participants was 39.7 ± 15.9 years. The overall prevalence of HBsAg was 10.03 % and 3.8 % for anti-HCV. Among the HBsAg-positive samples, HBV DNA was detected in all cases, with 68.2 % exhibiting a viral load exceeding 20,000 IU/mL. Elevated ALT was observed in 19.2 % of TB/HBsAg patients and in 30.0 % of TB/anti-HCV. About γ-GT, an elavated result was observed in 46.1 % of TB/HBsAg patients and 40.0 % of TB/anti-HCV patients. The results demonstrated a high prevalence of hepatitis B and intermediate exposure to HCV in TB patients. It is thus recommended that routine screening for these diseases be considered in TB patients.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100211"},"PeriodicalIF":1.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated levels of platelet-activating factor and syndecan-1 in severe dengue infections","authors":"Sri Masyeni ,&nbsp;I Made Wisnu Wardhana ,&nbsp;Pande Ayu Nayakasih Permatananda ,&nbsp;Arya Giri Prebawa ,&nbsp;Saraswati Laksmi Dewi ,&nbsp;Erni Juwita Nelwan","doi":"10.1016/j.jcvp.2025.100213","DOIUrl":"10.1016/j.jcvp.2025.100213","url":null,"abstract":"<div><h3>Background</h3><div>Severe dengue is a serious infection associated with cytokine storms.</div><div>Objectives: This study investigated the roles of platelet-activating factor (PAF), syndecan-1, and matrix metalloprotein-9 (MMP-9) in dengue severity.</div></div><div><h3>Study design</h3><div>Blood samples were collected to confirm the diagnosis of dengue infection, and to assess disease severity. Tests performed included non-structural protein 1 dengue test, immunoglobulin G/immunoglobulin M dengue tests, real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and a complete blood count. Patients with dengue infection were classified as having dengue fever or dengue hemorrhagic fever.</div></div><div><h3>Results</h3><div>The median levels of PAF, syndecan-1, and MMP-9 in all patients were 73.27 (14.2–769.1) pg/mL, 5.4 (2–64.3) pg/mL, and 197.8 (95.3–962.8) pg/mL, respectively. The levels of all three biomarkers were significantly higher in the dengue hemorrhagic fever and secondary infection groups; with <em>p</em> values &lt; 0.001. Multivariate analysis revealed that PAF and syndecan-1 levels significantly correlated with the severity of dengue infection. Syndecan-1 had the strongest correlation, with a correlation coefficient of 0.43, whereas PAF had a correlation coefficient of 0.30.</div></div><div><h3>Conclusions</h3><div>PAF and syndecan-1 were both independently associated with severe dengue; however, further longitudinal studies are required to validate their predictive potential.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100213"},"PeriodicalIF":1.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring humoral immune response following COVID-19 immunization and booster dose: A prospective study in tunisian healthcare workers","authors":"Chiraz Naffouti ,&nbsp;Hela Hannachi ,&nbsp;Wafa Aissi ,&nbsp;Ikram Ayari ,&nbsp;Fatma Ben Salem ,&nbsp;Manel Hamdoun ,&nbsp;Olfa Bahri","doi":"10.1016/j.jcvp.2025.100210","DOIUrl":"10.1016/j.jcvp.2025.100210","url":null,"abstract":"<div><h3>Background</h3><div>As SARS-CoV-2 vaccines are deployed worldwide, assessing the kinetics and magnitude of anti-SARS-CoV-2 antibodies post-vaccination at various time points is crucial to optimize immunization strategies. This study aims to evaluate the humoral response in healthcare workers (HCWs) after primary vaccination and booster doses both in the short and long term and to examine the effect of preexisting immunity, age, sex, and vaccine type on this response.</div></div><div><h3>Methods</h3><div>Prior to the primary vaccination, an initial serology was performed to determine the immunity to SARS-CoV-2. Based on the outcomes of this serology or the rapid diagnostic tests, participants were split into two groups: COVID-19-free and COVID-19-recovered people. In each group, serological tests were conducted one and six months following the first vaccination(M1,M6).The vaccines administrated were mRNA, viral vector and inactivated viral vaccines. The follow-up was done one and six months after the booster dose (mRNA vaccine) (M1B,M6B). Anti-SARS-CoV-2 anti-S IgG were evaluated using the Access SARS-CoV-2 IgGII® test (BECKMAN COULTER).</div></div><div><h3>Results</h3><div>A total of 319 HCWs were sampled. For COVID-19-recovered people, the median anti-S level was significantly higher at 130AU/mL(IQR 51.5–184) compared to 89AU/mL(IQR 34.1–145.4),<strong><em>p</em></strong> <strong>=</strong> <strong>0.0042.</strong> At every stage, there was a statistically significant increase in anti-S levels in adenovirus or inactivated vaccinations. Participants who received mRNA vaccines had significantly the highest anti-S levels at M1, M6, and M6B, according to post-hoc analysis. The anti-S level increased significantly one month after the third dose, from 12.7AU/mL(IQR 6.4–28.4) to 140.6AU/mL(IQR 88.6–258.5),<strong><em>p</em></strong> <strong>&lt;</strong> <strong>0.001</strong>. Six months after the booster dose, the anti-S titer dropped but remained positive at 40.8AU/mL(IQR22.5–91.3). In every time period, there was no correlation or association between anti-S level and age or sex.</div></div><div><h3>Conclusion</h3><div>The administration of mRNA vaccines allows to an enhanced humoral response in individuals recovering from COVID-19. Six months following the initial immunization, one dose has the same immunogenicity as two doses. However, a third dose of the mRNA vaccine should be given to lengthen the duration of the humoral in both COVID-19-free and COVID-19-recovered people. Booster doses should be administrated to high risk group who can transmit the disease to susceptible patient.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100210"},"PeriodicalIF":1.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of SARS-CoV-2: Experience with rapid immunochromatography tests and RT‒qPCR","authors":"David Alejandro Cabrera Gaytán ,&nbsp;Porfirio Felipe Hernández Bautista ,&nbsp;Clara Esperanza Santacruz Tinoco ,&nbsp;Julio Elias Alvarado Yaah ,&nbsp;Yu-Mei Anguiano Hernández ,&nbsp;Bernardo Martínez Miguel ,&nbsp;Alfonso Vallejos Parás ,&nbsp;Lumumba Arriaga Nieto ,&nbsp;Nancy Sandoval Gutiérrez ,&nbsp;Concepción Grajales Muñiz ,&nbsp;Alejandro Moctezuma Paz ,&nbsp;Leticia Jaimes Betancourt","doi":"10.1016/j.jcvp.2025.100207","DOIUrl":"10.1016/j.jcvp.2025.100207","url":null,"abstract":"<div><h3>Background</h3><div>Mexico has experienced six waves were experiences between 2019 and 2023 of coronavirus disease 2019 (COVID-19). In the first wave, diagnosis relied on RT‒qPCR; rapid tests for SARS‒CoV‒2 were introduced from the second wave onward. However, the patterns of results with this test in Mexico have not been documented in population-based studies.</div></div><div><h3>Objective</h3><div>To describe the temporal patterns of the results from RT-qPCR and rapid immunochromatography tests for SARS-CoV-2 detection from the second to the sixth epidemic wave in Mexico.</div></div><div><h3>Materials and methods</h3><div>This was a multicenter study at the national level. The operational definition of suspected cases of viral respiratory illness, confirmed cases of SARS-CoV-2 in Mexico, and data for asymptomatic individuals who required rapid testing between 2020 and 2023 were employed; testing was employed for the entirety of the four years. Positivity was estimated per epidemiological week, state, and condition for both tests. Spearman's correlation coefficient, trend chi-square analysis, and odds ratios with 95 % confidence intervals were used.</div></div><div><h3>Results</h3><div>A total of 1749,765 cases had RT‒qPCR data recorded from 2020 to 2023, and 8356,903 cases with rapid tests were conducted for virus identification. Compared with the rest of the country, the southeastern region exhibited different patterns. The positivity rate of rapid tests from the epidemiological surveillance system was lower than that of RT‒qPCR during interepidemics periods, whereas the positivity rate of rapid tests for symptomatic individuals was higher than that of RT‒qPCR tests over two years.</div></div><div><h3>Conclusion</h3><div>Rapid tests for SARS-CoV-2 identification in Mexico were affordable and timely at the local level. These tests revealed differing epidemic wave patterns in the southeastern region of the country.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100207"},"PeriodicalIF":1.6,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent nucleic acids from endemic human coronaviruses in adenoids: Do they enhance children's immune response to SARS-CoV-2 infection?","authors":"Kira Winkler ,&nbsp;Lucia Otten ,&nbsp;Alina Abramian ,&nbsp;Eva Weber ,&nbsp;Florian Winkler ,&nbsp;Niklas Klümper ,&nbsp;Anna Maria Schmidt ,&nbsp;Zahrasadat Safavieh ,&nbsp;Anna Maria Eis-Hübinger ,&nbsp;Stephan Herberhold","doi":"10.1016/j.jcvp.2025.100208","DOIUrl":"10.1016/j.jcvp.2025.100208","url":null,"abstract":"<div><h3>Introduction</h3><div>Human Coronaviruses (HCoVs), including HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E, are endemic viruses that circulate globally and infect humans. In contrast to SARS-CoV-2, which causes more severe symptoms, these endemic HCoVs typically induce mild cold symptoms and confer only temporary immunity [<span><span>1</span></span>,<span><span>2</span></span>]]. Understanding the presence and persistence of HCoVs in the human population, particularly in asymptomatic individuals, is crucial for understanding their potential role in immunity and viral dynamics.</div></div><div><h3>Methods</h3><div>This study aimed to investigate the presence of nucleic acids of endemic HCoVs (HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E) in individuals without symptoms of acute respiratory infection. A total of 78 adenoid tissue samples were collected from children (up to 10 years old) without current symptoms of airway infection. The samples were analyzed using RT-nested PCR to detect viral RNA.</div></div><div><h3>Results</h3><div>Of the 78 adenoid samples, 24 (30,8 %) tested positive for at least one type of endemic HCoV. Additionally, throat swabs were collected from 56 participants immediately before surgery. Endemic HCoV RNA was rarely detected in these throat swabs, with only 3 out of 56 samples testing positive.</div></div><div><h3>Discussion</h3><div>Our findings suggest the frequent presence of endemic HCoV nucleic acids in the lymphatic tissue of Waldeyer's ring, especially in children. This observation supports the concept of these viruses acting as immune triggers. The persistence of viral remnants in the adenoid tissue may contribute to continuous immune surveillance, which could have implications for immunity to future infections and for understanding viral dynamics in asymptomatic individuals.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100208"},"PeriodicalIF":1.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urgent attention for health care services preparedness to address rising human metapneumovirus (HMPV) cases","authors":"Md. Salman Sohel ,&nbsp;Safayet Jamil ,&nbsp;Md. Naimur Rahman","doi":"10.1016/j.jcvp.2025.100209","DOIUrl":"10.1016/j.jcvp.2025.100209","url":null,"abstract":"","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 2","pages":"Article 100209"},"PeriodicalIF":1.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The frequency of post-COVID-19 condition and its clinical relevance after COVID-19 disease of employees in facilities of preschool childcare","authors":"Michelle Nina Braun ,&nbsp;Anna Wolfschmidt ,&nbsp;Andrea Kaifie ,&nbsp;Ruediger Stephan Goertz","doi":"10.1016/j.jcvp.2024.100201","DOIUrl":"10.1016/j.jcvp.2024.100201","url":null,"abstract":"<div><h3>Objective</h3><div>Evaluation of the rate and symptoms of Post-COVID-19 condition in employees in childcare.</div></div><div><h3>Methods</h3><div>A structured questionnaire collected data from two distinct collectives: Collective 1 (C1) consisted of a prospective cohort of 44 employees after COVID-19 disease, whereas Collective 2 (C2) included 222 employees who were retrospectively interviewed. The questionnaire mainly focused on symptoms and wellbeing during or after COVID-19.</div></div><div><h3>Results</h3><div>The main symptoms of Post-COVID-19 condition were impairment of focus, fatigue/exhaustion, reduced stamina, headache and dyspnoea. 30 % of the employees in C1 and 7.6 % of C2 suffered from a clinically relevant Post-COVID-19 condition with impairment of the general wellbeing. According to the WHO definition, a Post-COVID-19 condition was found in 56.6 % (C1) and 25.5 % (C2).</div></div><div><h3>Conclusions</h3><div>A Post-COVID-19 condition was a common finding in both our collectives but did not automatically cause an impairment of general wellbeing.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100201"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a flow cytometry-based surrogate assay (FlowSA) for the detection of SARS-CoV-2 in clinical samples","authors":"Vinit Upasani ,&nbsp;Marjolein Knoester ,&nbsp;Daniele Pantano ,&nbsp;Lili Gard ,&nbsp;Jolanda M. Smit ,&nbsp;Bernardina T.F. van der Gun ,&nbsp;Adriana Tami ,&nbsp;Izabela A. Rodenhuis-Zybert","doi":"10.1016/j.jcvp.2025.100204","DOIUrl":"10.1016/j.jcvp.2025.100204","url":null,"abstract":"<div><h3>Introduction</h3><div>The current diagnostic methods for SARS-CoV-2 rely on quantitative RT-PCR. However, the presence of viral RNA in samples does not necessarily reflect the presence of an infectious virus. Therefore, the reliable detection of infectious SARS-CoV-2 in clinical samples is necessary to limit viral transmission.</div></div><div><h3>Methods</h3><div>We developed a flow cytometry-based surrogate assay (FlowSA), wherein the presence of infectious SARS-CoV-2 was detected using virus nucleocapsid-specific antibodies.</div></div><div><h3>Results</h3><div>We showed that FlowSA allows the detection of a wide range of viral titers of multiple SARS-CoV-2 variants. Furthermore, the assay was successfully used to detect infectious SARS-CoV-2 in nasopharyngeal swabs from SARS-CoV-2 positive individuals, including those with high Ct values. Notably, FlowSA identified the presence of infectious SARS-CoV-2 in biological specimens that scored negative for cytopathic effect (CPE) in cell culture and would otherwise be considered negative.</div></div><div><h3>Conclusion</h3><div>We propose that FlowSA can be adopted as an alternative to conventional CPE methods for viral diagnostics.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100204"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative evaluation of APRI and MELD scores in the prediction of complications of chronic hepatitis in patients infected with hepatitis B or C viruses in Lubumbashi, democratic republic of Congo","authors":"Arsène Kabamba-Tshikongo ,&nbsp;Adolphe Baleebenga ,&nbsp;Bernard Kalunga-Tompa ,&nbsp;Claude Mwamba-Mulumba ,&nbsp;Henry Manya-Mboni ,&nbsp;Cedrick Mutombo-Shakalenga ,&nbsp;Pierrot Mwamba-Tshilumba ,&nbsp;Sébastien Bontems ,&nbsp;Géraldine Dessilly ,&nbsp;Benoît Kabamba-Mukadi ,&nbsp;Albert Longanga-Otshudi","doi":"10.1016/j.jcvp.2024.100200","DOIUrl":"10.1016/j.jcvp.2024.100200","url":null,"abstract":"<div><div>The indication for treatment of viral hepatitis B and C depends on the degree of deterioration of liver function and secondarily viral load. APRI and MELD scores are WHO-validated tests for the assessment of liver fibrosis. They are inexpensive and non-invasive. Many patients suffer from viral hepatitis B or C in the Democratic Republic of Congo. These scores are an asset in the medical management of these patients. The objective of this study was to compare APRI and MELD scores in the prediction of fibrosis in patients with chronic viral hepatitis B in Lubumbashi. It included infected patients followed in the gastroenterology departments of the hospitals of Lubumbashi and the Center of Excellence and Expertise for Viral Hepatitis and other Pathologies (CEEHP). Biological parameters of patient samples were evaluated to calculate APRI and MELD scores. Analytical performance of APRI and MELD scores was evaluated by using liver biopsy as gold standard.</div><div>The APRI and MELD scores had a sensitivity of 100 % and a specificity of 93.5 and 88.6 %, respectively. In the fibrosis group of patients infected with HBV, the mean APRI score was of 1.89 whereas the mean MELD score was of 12.4 Incorporating these scores in routine clinical practice could reduce the morbidity rate, the costs related to the practice of liver biopsy and thus improve the routine management of viral hepatitis in Lubumbashi.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100200"},"PeriodicalIF":1.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}